key: cord-0734598-e5c2oyst
authors: Ma, Xiaoyi; Guo, Shiyu; Ruan, Shuangrong; Liu, Yao; Zang, Jie; Yang, Yushan; Dong, Haiqing; Li, Yan; Ren, Tianbin; An, Maomao; Li, Yongyong
title: HACE2-Exosome-Based Nano-Bait for Concurrent SARS-CoV-2 Trapping and Antioxidant Therapy
date: 2022-01-22
journal: ACS Appl Mater Interfaces
DOI: 10.1021/acsami.1c19541
sha: 6cc9e621e131a8718575e27bc29185f77a108861
doc_id: 734598
cord_uid: e5c2oyst

[Image: see text] Corona Virus Disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is seriously threatening human health. Following SARS-CoV-2 infection, immune cell infiltration creates an inflammatory and oxidative microenvironment, which can cause pneumonia, severe acute respiratory syndrome, kidney failure, and even death. Clinically, a safe and effective treatment strategy remains to be established. Herein, a nano-bait strategy for inhibition of SARS-CoV-2 infection by redirecting viral attack while simultaneously relieving inflammation is developed. Specifically, the nano-bait was based on the exosome-sheathed polydopamine (PDA@Exosome) nanoparticles, which were generated by exocytosis of the PDA nanoparticles from H293T cells. In this approach, PDA@Exosome inherits from the source cells of H293T cells a surface display of ACE2 through pre-engineered expression. The resulting PDA@Exosome can compete with ACE2-expressing epithelial cells for S protein binding, in either the pre-exposure or post-exposure route. Moreover, relying on the ability of PDA to intercept and deactivate radical species, the PDA@Exosome can significantly attenuate the level of inflammatory cytokines by mediating oxidative stress, a major cause of organ injury. Due to its high trapping, multiple antioxidant ability, and good biocompatibility, the HACE2-exosome based nano-bait is a promising robust antiviral nanotherapeutics for the ongoing COVID-19 pandemic.

COVID-19 (Corona Virus Disease 2019), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has led to a severe global public health crisis 1,2 due to its high pathogenicity and transmissibility. 3, 4 Once infected, some patients suffered from the rapidly deteriorated conditions within a short period. Nevertheless, effective therapeutic options for COVID- 19 patients are yet to be established as cases of severe pneumonia, acute respiratory distress syndrome, and multiple organ failure continued to be reported. 5, 6 With rising global demand, effective treatment options and infection prevention are urgently needed.

It has been established that the SARS-CoV-2 virus mainly binds to the ACE2 (angiotensin converting enzyme 2) receptor expressed on the alveolar epithelial cells through its surface spike protein (S protein) in order to enter the human host cell and complete the virus life cycle. The susceptibility to S protein is positively correlated with the level of ACE2 expression. Therefore, blocking the S protein-ACE2 binding process is recognized as one of the effective therapeutic strategies for COVID-19 therapy. 7−9 Therefore, anti-SARS-CoV-2 neutralizing antibodies, soluble recombinant ACE2 proteins, 10−12 as well as natural active compounds (baicalin or hesperidin) have been used to block the S protein-ACE2 binding for viral infection inhibitions. 13 Meanwhile, material scientists also contributed by offering several solutions to fight the virus. For example, Zhang et al. developed nano-sponges for absorbing the virus, which can minimize cellular infectivity and discourage SARS-CoV-2 contagion. 14 Chen et al. reported a decoy nanoparticle that presents abundant cytokine receptors on its surface, which can be used to adsorb the virus and neutralize inflammatory cytokines. 15 Beyond the direct blockage of viral attack, the overwhelmed local inflammatory response must also be taken into account as part of COVID-19 treatment because it is the major reason for the progression of severe pneumonia in COVID-19 patients. 9,16−18 One of the symptoms of COVID-19 is known as the cytokine release syndrome (CRS), that is, cytokine storm, which can lead to multiple-organ failure. CRS is considered as an important cause of death in severe pneumonia patients. The damages caused by CRS can even exceed those directly attributed to the SARS-CoV-2 virus itself. Therefore, new therapeutic strategies that can effectively control the CRS induced by SARS-CoV-2 while relieving any oxidative injures are urgently needed. 19, 20 To achieve this aim of developing an effective therapeutic option for COVID-19 patients, we propose a concept that leverages H293T-exosome-based nano-bait. This therapeutic alternative not only halts new infection, but also provides relief for oxidative stress in order to minimize organ injury.

The H293T-derived ACE2-expressing exosome nano-bait displays a large number of ACE2 receptors on its surface, similar to the source epithelial cells. PDA nanoparticle, a melanin-like structure, was integrated as the inner core due to their strong antioxidative capacity. 21 The nano-bait was prepared by exocytosis of the PDA materials from H293T cells (called PDA@Exosome). For safety consideration, spike proteins from the surface of the virus were used as a substitute to validate the competitive binding capacity of the nano-bait. PDA@Exosome has been shown to compete for S protein binding with 293Tcells either pre-exposure or post-exposure. 22 PDA@Exosome may also enhance the binding of ACE2 and S protein. A previous study has also reported that multicopy display plays a major role in increasing the force of interface interaction. 23 Our results suggest that PDA@Exosome is a promising therapeutic strategy for COVID-19. The PDA@Exosome can be used as a bait for the SARS-CoV-2 virus by directing the viral attack away from cells, while also demonstrating potent antioxidative benefits.

2.1. Preparation and Characterization of the Exosomes-Sheathed PDA Nanoparticles. As the ACE2 protein receptor cluster is the basis for the nano-bait's competitive binding ability, we constructed 293T cells that highly express ACE2 receptors (called H293T cells). After H293T cells were incubated with PDA, PDA was endocytosed by cells and later exocytosed. The exocytosis PDA (PDA@Exosome) was collected by gradient ultracentrifugation (as shown in Scheme 1B). TEM images of PDA ( Figure 1a ) and exosomes ( Figure  1b) revealed that PDA exhibited a uniform spherical shape. A thick membrane appeared on the surface of PDA@Exosome compared with PDA ( Figure 1c ). Due to the encapsulation of the exosome membrane, PDA@Exosome displayed irregular morphology, and its particle size increased. DLS analysis showed that the size of PDA and PDA@Exosome was 105 and 341 nm, and the corresponding PDI was 0.101 ± 0.021 and 0.658 ± 0.073 (Figure 1d ), respectively. The surface potential of PDA and PDA@Exosome was 1.16 ± 0.23 and −8.99 ± 0.66 mV, respectively (Figure 1e ). The successful synthesis of PDA@Exosome was verified by two approaches. First, the absorption spectrum was used to detect the specific absorption of PDA. As shown in Figure 1f , PDA@Exosome showed the same absorption peak as PDA at approximately 220 nm wavelength, while exosomes do not have obvious absorption peaks within the ultraviolet range of 200−800 nm. Second, the Western blot experiment was performed to verify ACE2 protein expression. As observed in Figure 1g , both 293Texosome and PDA@293T-exosome extracted from 293T cellsexpressed ACE2 protein. The protein expressions of H293T exosome and PDA@H293T-exosome groups were obviously higher than the other two groups. To further prove that PDA@ Exosome were sheathed with the exosome membrane structure, Western blot experiments showed that exosome biomarkers Alix and CD9 were detected. In contrast, calnexin, a protein only detected in whole cell lysates, was not shown in exosomes or PDA@exosome group. It proved the existence of exosomes. Moreover, the size of PDA@Exosome remained almost constant even after incubating in PBS with or without 10% fetal bovine serum (FBS) for 8 days (Supporting Information Figure S1 ).

In Vitro Characteristics of PDA as the Nano-Bait Core. To explore the biological function of PDA, the interaction of PDA with H293T cells was investigated. PDA was labeled with red rhodamine dye (Rho) to visualize the process of endocytosis by H293T cells (named as PDA-Rho). As shown in Figure 2a , both Rho and PDA-Rho showed specific absorption of Rho at approximately 550 nm. The absorption spectrum indicated successful combination of Rho and PDA. In order to observe the endocytosis process, H293T cells were incubated with PDA-Rho (at PDA concentration of 200 μg/mL, ultraviolet spectrophotometry was used to establish its concentration). Intracellular PDA-Rho fluorescence was observed by live cell workstation (Figure 2b ). The various time point fluorescence intensities were also detected and was measured semiquantitatively by ImageJ software, and the results indicated that intracellular PDA-Rho fluorescence value increased in a time-dependent manner and gradually reached a plateau at 6 h (Supporting Information Figure S2 ). We investigated the cellular uptake mechanism of PDA by using some endocytosis inhibitors. 24 OctMAB (30 μM) is a dynamin I inhibitor, and amiloride hydrochloride (5 mM) is the inhibitor of ENaC and micropinocytosis. H293T cells were incubated with two inhibitors in 37°C for 30 min and then cultured with PDA-Rho (at a PDA concentration of 200 μg/ Figure S3 ). Micropinocytosis may be one of the mechanisms of PDA endocytosis. The cytotoxicity of different concentrations (from 10 to 1000 μg/mL) of PDA was detected by CCK-8 assay. Overall, PDA demonstrated good biocompatibility. Even when PDA concentration reached 1000 μg/mL, almost no cytotoxicity was observed and the cell viability of PDA still reached 80% (Figure 2e ).

PDA nanoparticles are nanostructures that are produced by oxidation−polymerization of dopamine monomers. PDA has demonstrated diverse biomedical applications, including its role in anti-oxidative therapy. This characteristic is also one of the reasons we select PDA as the core of our nano-bait. In Figure 2c , a decrease of fluorescence signal around 425 nm in the fluorescence spectra was detected in the presence of PDA NPs with various concentrations (from 12.5 to 200 μg/mL), which confirmed that PDA NPs could efficiently eliminate HO • . The scavenging efficiency of PDA nanoparticles toward HO • followed a concentration-dependent manner and could be enhanced with the increasing of the concentration of PDA. When the concentration of PDA NPs was increased to 0.2 mg/ mL, nearly 60% of the HO • were removed from the system. As shown in Figure 2d , a strong absorbance signal could be As shown in Figure 2f , the anti-inflammation activity of PDA in vitro was determined by DCFH-DA probe. Specifically, 293T cells were co-incubated with PBS, S protein, and S protein + PDA groups. The S protein group showed high fluorescence of DCF, while the other two groups presented weak fluorescence signals. The results showed that the level of intracellular ROS in the S protein group was higher than that in the S protein + PDA group, which supported the antioxidative ability of PDA in vitro. The fluorescence intensities were semiquantitatively measured by ImageJ software ( Figure  2g ).

Flow cytometry analysis was used to further analyze the ROS level derived from 293T cells after treatment of three groups. As shown in Figure 2h , 293T cells cocultured with S protein produced certain levels of endogenous ROS; however, the relative fluorescence intensity was increased by 2.1-fold when compared with the PBS (control) group. In contrast, ROS levels were decreased by 1.4-fold when cells were treated with S protein + PDA.

Vitro. PDA@Exosome was used as nano-bait to inhibit the SARS-CoV-2 virus from invading the body by redirecting viral attacks away from cells. S protein on the surface of the virus was used as a substitute in this study to validate the competitive binding capacity of the nano-bait. S protein has been shown to competitively bind with the ACE2 receptors on the cell membrane in vitro. 25 To visualize this process, FITC fluorescent dye was used to label S protein. The fluorescence intensity on the cell surface was used to examine if S protein is indeed directed to the nano-bait. During the 1, 2, 4, and 6 h of co-incubation, the level of S protein fluorescence intensity on the cell surface increased in a time-dependent manner and finally reached a plateau level at 6 h. Therefore, 6 h was chosen as the co-incubation time of S protein, PDA@Exosome, and cells (Supporting Information Figure S4 ).

To demonstrate that our nano-bait can not only bind with free S protein, but also compete for S protein that has bound to 293T cells, we set up an experiment with the following groups ( Figure 3a ). Group1 (G1) is the control group, in which cells were treated with PBS only and incubated at 37°C for 4 h; G2 is the S protein group, in which cells were incubated with FITC-labeled S protein at 37°C for 4 h; in G3, S protein was incubated with 293T cells for 2 h in advance, followed by coincubation with PDA@Exosome for another 2 h under the same temperature condition; in G4, S protein was incubated with PDA@Exosome for 2 h, and then added to 293T cell culture dish to continue the incubation for another 2 h. Specifically, in G3, S protein was exposed to ACE2 receptors Research Article on the cell surface first, followed by the introduction of our nano-bait PDA@Exosome. This setting allowed us to investigate if PDA@Exosome (at exosomes protein dosage of 20 μg/mL) could compete for S protein that has already bound to cells. Reversely, in G4, S protein was exposed to the overexpressed ACE2 receptors on the surface of nano-bait first, then subsequently introduced into cell culture, which allowed for the examination of the strength of binding between S protein and PDA@Exosome in the presence of cell competitors.

As shown in the live cell workstation imaging results ( Figure  3b ), high fluorescence expression of S protein on the cell membrane was observed only in G2. The fluorescence intensities were semiquantitatively measured by ImageJ software (Figure 3d ). Flow cytometry analysis was used to further quantify the results (Figure 3c ). After incubation with PDA@Exosome, the fluorescence intensity of S protein on the cell surface in G3 was significantly decreased by 2.2-fold when compared with G2. In G3, the S protein that was once bound to the cell surface was redirected to bind with the nano-bait. Expression levels of the three inflammatory cytokines 12 h after S proteins were transtracheal-injected, followed by 12 h after different treatment groups were transtracheal-injected, in (d) peripheral blood serum and (e) lung tissue grinding fluid, as detected by the ELISA kit. (n = 3) *p < 0.05, **p < 0.01, ***p < 0.001, ns: P > 0.05, no significance between groups. Furthermore, as demonstrated in G4, S protein binding with PDA@Exosome was strong enough that almost no S protein fluorescence was observed on the 293T cell surface. These results support that the highly expressed ACE2 receptors on the surface of PDA@Exosome exhibit strong competitiveness for S protein binding that the nano-bait is capable of redirecting S protein away from cells in vitro. In order to assert the necessity of the PDA core, a batch of normal H293T exosomes without PDA were purified (N-Exo). The same methods described above were used to compare the competitive binding ability of N-Exo (see in Supporting Information Figure S5 ). G5 and G6 were similar to G3 and G4, but with the PDA@Exosome replaced by N-Exo. As shown in Supporting Information Figure S6 , without the PDA core, most FITC-labeled S protein remained bound to receptors on the cell membrane, which indicated that the binding of S protein to the ACE2 receptor on 293T cells could not be effectively prevented by N-Exo. The greater competitive binding ability of PDA@Exosome may due to the PDA core. PDA as a solid core can provide a certain degree of adhesion, which may improve the stability of exosomes with liposome structure, which is vital to its success as a therapeutic strategy against CRS in COVID-19.

To further clarify that the reduced S protein fluorescence intensity is due to the binding of S protein to the nano-bait, the fluorescence expression of FITC-labeled S protein bound with PDA@Exosome was observed through live cell workstation. PDA-Rho was incubated with cells, followed by the extraction of PDA-Rho@Exosome. The PDA-Rho@Exosome was coincubated with FITC-labeled S protein under the same conditions as mentioned above. When combined, PDA-Rho@Exosome and FITC-labeled S protein would attract by and attach to the cation-coated cell slides. Expectedly, an obvious fluorescence overlap was observed, which demonstrated a successful combination (Supporting Information Figure S7 ).

2.4. Therapeutic Effect of Nano-Bait In Vivo. S protein alone can damage vascular endothelial cells and induce inflammation. 26 In this study, transtracheal injection of S protein was used to induce inflammation in our mice model. S protein at a dosage of 5.5 nmol/kg was transtracheal injected into 7-week Balb/c mice. Subsequently, the orbit blood and the lung tissue of mice were collected at different time periods and were prepared as serum and grinding fluid, respectively. The expression of inflammation-related factors was measured and observed by a commercial ELISA kit. IL-6, IL-1β, and TNF-α have been found to be the representative inflammatory cytokines in the current coronary pneumonia cytokine release syndrome. In our research, significant increases in the levels of IL-1β, IL-6, and TNF-α were observed, with the expression level of IL-6 being the highest among the three inflammatory factors. Continuously high levels of cytokines in the S protein injected mice represented the success of our inflammation mice model (Figure 4b ). Because S protein-induced inflammation occurs locally in the lungs, the cytokine expression levels in the mice lung tissue grinding fluid were higher than those in the peripheral blood (Figure 4c) .

To further explore the anti-inflammatory effect of PDA@ Exosome in vivo, mice were randomly divided into five groups (n = 5). The blank group consisted of the healthy mice, only PBS placebo was applied to the inflammation mice model in the control group. As we can see in Figure 4a , 12 h after S protein was transtracheal-injected, free N-EXO at protein dosage of 2.5 mg/kg, free PDA at 1 mg/kg, and PDA@ Exosome at protein dosage of 2.5 mg/kg (BCA quantitative assay was used to detect protein content, referenced by ref 27) were transtracheal-injected into the inflammation mice. Peripheral blood (Figure 4d ) and lung tissue grinding fluid (Figure 4e ) were collected after 12 and 24 h, respectively. The results showed that, after treatment, the expression levels of inflammatory factors in the control group remained high, while the levels in other treatment groups were decreased to varying degrees. Among them, the PDA@Exosome group showed the most impressive inflammation-suppressing effect. The results suggested that PDA@Exosome could play a role in reducing the levels of inflammatory factors during cytokine release syndromes and ultimately relieving lung inflammation. 2.5. Biosafety of PDA@Exosome In Vivo. S protein infection of mice is associated with the development of mild pathological changes in the lungs. Figure 5a shows the pathological changes of the lung (S protein modeled group), including atypical epithelial hyperplasia (arrow a), dilute lumen (arrow b), and increased infiltrated of lymphocytes (arrow c), which supports the hypothesis that lung inflammation caused by S protein can lead to tissue damage. All of the pathological changes led to pulmonary edema and concurrent ventilation disorders in mice. After treatment with our nano-bait, lung tissue injury observed in the slices was significantly improved to an extent that resembled the normal lung tissue structure in the control group. The safety of the PDA@Exosome and the other treatment groups was further evaluated in vivo, and no apparent histopathological changes in the heart, liver, spleen, or kidney were observed (Figure 5b ).

In this study, PDA@Exosome served as a nano-bait for the treatment of cytokine release syndrome. The anti-inflammation capacity of PDA and the competitive binding ability of exosome allowed the nano-bait to re-direct viral attack via S protein binding and to control excessive immune response. Hence, the application of PDA and exosomes in this study served as a form of combination therapy that exhibited a synergistic treatment effect. In the in vivo experiment, inflammation mice model treated with PDA@Exosome experienced a significant reduction in the levels of inflammatory factors and demonstrated milder lung tissue damage when compared to other treatment groups. Looking into the future, the strategy of nano-bait by this work may provide a safe and economic route for COVID-19 treatment due to convenient and biocompatibility of PDA. Moreover, the principle of nanobait strategy is advantageous to address the viral mutation because its function relies more on human S protein but not virus structure. 4.2. Cell Lines. 293T cells were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). In order to obtain 293T cells with high expression of ACE2 protein, H293T was prepared by the lentiviral transfection method. 293T cells were infected with lentivirus and selected with G418 (5 μg/mL) to obtain target cells with a high degree of stability.

Both H293T cells and 293T cells were cultured in DMEM (high glucose) medium with 10% FBS, penicillin (100 U/mL) and streptomycin (100 μg/mL) at 37 O C with 5% CO 2 . G418 geneticin was added to H293T cells for cell screening.

4.3. S Protein Expression and Purification. The coding sequence of SARS-CoV-2 RBD (residues 319−541, UniProtKB P0DTC2 (SPIKE_SARS2)) was cloned into the mammalian expression vector PcDNA3.4 with a C-terminal his-tag. The expression vectors were transiently transfected into HEK Expi 293F cells (Thermo Fisher Scientific) using polyethylenimine. The cell supernatant was purified by AmMag Ni Magnetic beads (Gen-Script). 28 4.4. Synthesis of FITC-Labeled S Protein. FITC powder was dissolved in DMSO to the same concentration as the S protein. Then, it was mixed with 0.1 M NaHCO 3 solution by stirring at room temperature at 180 rpm for 4−6 h. After reaction, the solution was ultrafiltered or dialyzed to remove unbound fluorescent dye and stored at −80 O C.

4.5. Synthesis of PDA. For PDA synthesis, 10 mM 3hydroxytyramine hydrochloride and 1 M NaOH solution were mixed at room temperature for 5 h. After reaction, the liquid was collected and centrifuged at 10 000 rpm for 20 min, followed by the removal of the supernatant. The PDA was washed twice with ddH 2 O, and the final products were stored at 4°C. 4.6. Synthesis of Rho-Labeled PDA. Rhodamine B powder and PDA nanoparticles of the same mass concentration were mixed and incubated overnight. Ultrafiltration or dialysis was performed to remove unbound rhodamine dye. The rhodamine-labeled PDA (200 μg/mL) was used to visualize the cellular uptake process. 4.7. PDA@Exosome Purification. The differential ultracentrifugation method was used to extract exosomes. First, H293T cells were treated with PDA at a concentration of 200 μg/mL in a 10 cm 2 dish, where PDA was endocytosed by the cells. After 6 h, the medium was discarded and replaced with fresh medium. The culture was continued for another 16−20 h. Cell culture medium was sequentially centrifuged at 300g for 10 min, 1000g for 10 min, and 10 000g for 30 min. Then, the supernatant was ultracentrifuged at 80 000g for 2 h. 4.8. N-EXO Purification. Exosomes were purified using the differential ultracentrifugation method. 29 H293T cells were incubated in exosome-free DMEM medium for 36−48 h. Cell culture medium was collected and centrifuged at 300g for 10 min, 1000g for 10 min, and 10 000g for 30 min. Then, the supernatant was ultracentrifuged at 100 000g for 2 h. 4.9. Cytotoxicity of PDA Against H293T Cells. The in vitro cytotoxicity of PDA against H293T cells was estimated by Cell Counting Kit-8 (Beyotime). H293T cells were seeded in 96-well plates (5 × 10 4 cells/well) and cultured for 24 h. Then, H293T cells were incubated with different concentrations of PDA (10−1000 μg/ mL) for 30 min. CCK-8 reagent was then added to each well, and the results were detected using a multifunctional Microplate reader (Tecan).

4.10. Detection of Reactive Oxygen Species. Intracellular ROS generation was detected using DCFH-DA (10 μΜ) as the sensor. Live cell workstation and flow cytometry were used to perform imaging. 293T cells were seeded in six-well cell culture plate and incubated overnight. Following removal of the medium, cells were treated with PBS, S protein, and S protein + PDA and incubated for another 4 h. Subsequently, DCFH-DA was added and incubated for 30 min. Then, medium was removed and cells were washed twice with PBS. Flow cytometry analysis was performed by following similar manipulations as stated before following harvest of cells from a sixwell plate. . O 2 •− scavenging efficiency of PDA NPs was achieved by measuring the inhibition ratio of photoreduction of NBT. Solutions contain riboflavin (20 μM), methionine (12.5 mM), NBT (75 μM), and PDA NPs (from 12.5 to 200 μg/mL). Riboflavin was prepared in 0.1 M NaOH; others were prepared in PBS (25 mM, pH 7.4). The mixtures were illuminated upon ultraviolet radiation for 30−60 min. After illumination, the absorbance of mixtures was measured. The sample containing riboflavin, methionine, and NBT after illumination was defined as positive control. All the experiments were carried out in dark without illumination.

4.13. Inflammation Model and Transtracheal Drug Delivery Treatment. High intensity and sustained increase in cytokine levels were characteristics of cytokine release syndrome. To induce inflammation, S protein was injected at a dosage of 5.5 nmol/kg into the lungs of mice through the trachea. The invasion of foreign substances caused lung infections and activated the immune system's line of defense. Excessive activation could lead to cytokine release syndromes.

4.14. Enzyme-Linked Immunosorbent Assay. After exposure to different treatments, mice orbital blood was obtained, maintained for 30 min, and centrifuged at 10,000 g for 10 min. The serum was collected, and the levels of IL-1β, IL-6, and TNF-α were analyzed using the enzyme linked immunosorbent assay (ELISA) kit (Dakewe, Shenzhen, China) by following the manufacturer's instructions.

4.15. Western Blotting. Cell lysate was prepared using lysis buffer (50 mM Tris, 150 mM NaCl, 1% Triton, pH 8) supplemented with Protease Inhibitor Cocktail (Sigma) at a concentration of 4 × 10 6 cells in 100 μL of buffer. After incubation for 20 min on ice, samples were centrifuged at 18 500g for 20 min. The pellet was discarded, and the supernatant was kept for further analysis. The supernatant was denatured in a metal bath at 95°C for 5 min and then mixed with sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) sample loading buffer. Then, the processed protein samples were separated by SDS-PAGE electrophoresis and transferred to PVDF membrane. The membrane was blocked and incubated with anti-human ACE2 antibody (clone EPR4435 against extracellular domain, Abcam 108252) overnight at 4°C and then incubated with a second antibody at room temperature for 1 h. The protein bands were then visualized using enhanced chemiluminescence kit, and ImageJ was used to analyze the level of protein expression.

4.16. Statistical Analysis. All values in the present study are presented as mean ± SD. All animal studies are performed after randomization. Analysis of flow cytometry data is performed by FlowJo 10.0 software. The significance of differences between the groups is analyzed by one-way analysis of variance (ANOVA) with SPSS 25.0. Significant differences between or among the groups are indicated by *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

The Supporting Information is available free of charge at https://pubs.acs.org/doi/10.1021/acsami.1c19541.

Hydrodynamic diameter of PDA@Exosome incubated in PBS with or without 10% FBS for different durations; phagocytosis of PDA by H293T cells characterized by a living cell workstation; investigation of the cellular uptake mechanism of PDA by using endocytosis inhibitors; time-dependent experiments of S protein binding to 293T cells characterized by living cell workstation; schematic illustration of the binding experiments; fluorescence images and semiquantitative analysis of cells after incubation with G5 and G6 groups; and fluorescence images of FITC-labeled S protein combined with PDA-Rho@Exosome (PDF) 51773154, 31771090, and 81871315), Shanghai Science and Technology Innovation (18JC1414500), and Young Hundred-Talent Program of Tongji University.

Outbreak of Pneumonia of Unknown Etiology in Wuhan, China: The Mystery and The Miracle

The COVID-19 Pandemic: a Global Health Crisis

Severe Covid-19

A Systematic Review and Meta-analysis of Published Research Data on COVID-19 Infection Fatality Rates

Clinical Features of Patients Infected With

Review of the Clinical Characteristics of Coronavirus Disease 2019 (COVID-19)

Angiotensin-converting Enzyme 2 Protects from Severe Acute Lung Failure

SARS Coronavirusinduced Lung Injury

COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome

Neutralizing Human Recombinant Antibodies Selected from Pre-pandemic Healthy Donors Binding at RBD-ACE2 Interface

A SARS-CoV-2 Neutralizing Antibody with Extensive Spike Binding Coverage and Modified for Optimal Therapeutic Outcomes

Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity

Decoy Nanoparticles Protect Against COVID-19 by Concurrently Adsorbing Viruses and Inflammatory Cytokines

The Cytokine Storm and COVID-19

Immunophenotyping of COVID-19 and Influenza Highlights the Role of Type I Interferons in Development of Severe COVID-19

COVID-19: Consider Cytokine Storm Syndromes and Immunosuppression

Cytokine Storm in COVID-19: Pathogenesis and Overview of Anti-inflammatory Agents Used in Treatment

Melanin-Like Nanomaterials for Advanced Biomedical Applications: A Versatile Platform with Extraordinary Promise

Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy

Extracellular Vesicles Containing ACE2 Efficiently Prevent Infection by SARS-CoV-2 Spike Protein-containing Virus

Structure, Function, and Evolution of Coronavirus Spike Proteins

COVID-19: The Vasculature Unleashed

Dosing Extracellular Vesicles

Evolution of the Novel Coronavirus from the Ongoing Wuhan Outbreak and Modeling of Its Spike Protein for Risk of Human Transmission

Tumor Exosomebased Nanoparticles are Efficient Drug Carriers for Chemotherapy

Polydopamine Nanoparticles as Efficient Scavengers for Reactive Oxygen Species in Periodontal Disease